Renaissance Technologies’s Verrica Pharmaceuticals VRCA Stock Holding History

Renaissance Technologies’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$171K	Buy	32,360 +5,960	+23%	+$38.2K	﹤0.01%	2941
2025 Q4	$219K	Sell	26,400 -2,791	-10%	-$15.5K	﹤0.01%	2863
2025 Q3	$126K	Buy	29,191 +20,471	+235%	+$123K	﹤0.01%	3226
2025 Q2	$46.2K	Buy	+8,720	New	+$46.9K	﹤0.01%	3405
2025 Q1	–	Sell	-23,330	Closed	-$163K	–	3874
2024 Q4	$163K	Buy	23,330 +8,534	+58%	+$93.8K	﹤0.01%	3215
2024 Q3	$215K	Buy	14,796 +10,243	+225%	+$461K	﹤0.01%	3105
2024 Q2	$332K	Buy	+4,553	New	+$350K	﹤0.01%	2869
2023 Q4	–	Sell	-6,810	Closed	-$265K	–	4174
2023 Q3	$265K	Sell	6,810 -9,120	-57%	-$463K	﹤0.01%	2990
2023 Q2	$919K	Buy	15,930 +10,280	+182%	+$624K	﹤0.01%	2517
2023 Q1	$367K	Sell	5,650 -9,987	-64%	-$604K	﹤0.01%	3027
2022 Q4	$430K	Sell	15,637 -7,393	-32%	-$197K	﹤0.01%	3034
2022 Q3	$672K	Buy	23,030 +18,240	+381%	+$625K	﹤0.01%	2734
2022 Q2	$92K	Buy	+4,790	New	+$241K	﹤0.01%	3873
2020 Q1	–	Sell	-1,390	Closed	-$221K	–	3838
2019 Q4	$221K	Buy	+1,390	New	+$205K	﹤0.01%	3168

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies's VRCA Position: Q1 2026 in Review

Renaissance Technologies increased its Verrica Pharmaceuticals (VRCA) stake by 23% in Q1 2026, buying an estimated $38.2K and bringing the position to 32,360 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Renaissance Technologies first reported a position in VRCA in Q4 2019 and has held it in 14 quarters since. The position peaked at $919K in Q2 2023. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

Renaissance Technologies held 32,360 shares of Verrica Pharmaceuticals worth $171K as of Q1 2026.
Renaissance Technologies bought 5,960 Verrica Pharmaceuticals shares in Q1 2026, an estimated $38.2K.
Verrica Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2941 holding.
Renaissance Technologies first reported a position in Verrica Pharmaceuticals in Q4 2019 and has held it in 14 quarters since.
Renaissance Technologies's Verrica Pharmaceuticals position peaked at $919K in Q2 2023.
39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.